MOTS-c and NAD+ both live in the mitochondria conversation, which makes them look interchangeable from a distance — they are not. NAD+ is infrastructure: the coenzyme mitochondria burn through in every energy-producing reaction. MOTS-c is a signal: a peptide encoded in mitochondrial DNA that tells the rest of the cell to adjust its metabolism. Comparing them is comparing fuel-system maintenance with a regulatory switch — different mechanisms, different evidence stages, different research questions.
| Attribute | MOTS-c | NAD+ |
|---|---|---|
| What it is | Peptide encoded in mitochondrial DNA (a "mitokine" signal) | Coenzyme present in every living cell |
| Studied role | Metabolic regulation via AMPK; exercise-mimetic signalling | Energy metabolism, redox reactions, DNA-repair enzyme fuel |
| Age relationship | Levels rise with exercise; decline with age (observational) | Well-documented decline with age across tissues |
| Key evidence | Animal: improved insulin sensitivity, obesity protection (Cell Metabolism 2015) | Deep basic-science literature; precursor trials raise levels in humans |
| Human data | Very small early-phase studies only | Thin for injectable NAD+ itself; more for oral precursors |
| Evidence stage | Discovery-stage (identified 2015) | Mature biology, immature supplementation evidence |
| In the Body Pharm catalogue | Yes (MOTS-C 32) | Yes (NAD+ 1000) |
NAD+ participates directly in the chemistry of energy production — it is consumed, recycled and required, which is why its age-related decline draws so much research attention. MOTS-c does no metabolic work itself; it activates AMPK signalling in skeletal muscle, shifting how cells handle glucose and fat. In the 2015 discovery work and follow-ups, administering it to mice improved insulin sensitivity and blunted diet-induced obesity — a regulatory effect, not a fuel effect.
NAD+ biology is textbook science with decades behind it; what is young is the evidence that supplementing it changes outcomes. MOTS-c is the mirror image: the whole field is barely a decade old, the animal data is striking, and human interventional data is limited to very small early studies. Neither compound has a completed clinical programme or an approved use.
Because one is a signalling peptide and the other a metabolic substrate, the two are not alternatives answering the same question. Energy-metabolism research programmes often look at regulatory signals and coenzyme availability as separate variables — which is the honest way to read a catalogue that lists both.
No. NAD+ is a coenzyme consumed in energy production; MOTS-c is a signalling peptide that regulates metabolism via AMPK. They intersect at mitochondria but act at completely different levels.
Both are thin, differently: NAD+ has mature basic science but limited trial data for supplementation itself; MOTS-c has striking animal results but only very small early human studies.
No. Neither MOTS-c nor injectable NAD+ has a regulator-approved indication or validated human dosing schedule anywhere.
MOTS-c levels rise with exercise in humans, and administering it to animals reproduced part of exercise’s metabolic signature — the origin of its "exercise-mimetic" label. That label describes animal findings, not a demonstrated human effect.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy